Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

Fineline Cube Apr 21, 2026
Company Deals Digital

AI Healthtech Firm WeiMai Files for Hong Kong IPO, Touting CareAI Platform and Leadership in Hospital-Linked Disease Management

Fineline Cube Apr 21, 2026
Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Fineline Cube Apr 21, 2026
Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status

Fineline Cube Apr 21, 2026
Company Drug

Hengrui Launches Pediatric Trial of Dual GIPR/GLP-1R Agonist HRS9531 in Overweight and Obese Adolescents Following NMPA Clearance

Fineline Cube Apr 21, 2026
Company Drug

Eisai’s Fycompa Gains New Indication for Generalized Tonic-Clonic Seizures in China

Fineline Cube May 11, 2024

Eisai Co Ltd (TYO: 4523), a Japanese pharmaceutical company, has announced that its antiepilepsy drug...

Company Deals

Ribobay Pharma and General Biol to Commence GMP-Grade Oligonucleotide Manufacturing Services

Fineline Cube May 11, 2024

Shanghai-based contract research, development, and manufacturing organization (CRDMO) Ribobay Pharma has announced plans to commence...

Company Policy / Regulatory

BioSecure Act Advances in US, Aiming to Curb Ties with Chinese Bioscience Firms

Fineline Cube May 11, 2024

US legislators are working expeditiously to finalize the BioSecure Act, legislation that, if enacted, would...

Company Drug

Jacobio Pharma’s KRAS G12C Inhibitor Gains NMPA Approval for Phase III CRC Study

Fineline Cube May 11, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced that it has...

Company Deals

Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe’s China Subsidiary

Fineline Cube May 11, 2024

Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to...

Company Drug

Qilu Pharmaceutical Achieves First Approval for Generic Bendamustine in China

Fineline Cube May 11, 2024

The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic bendamustine,...

Company Deals

Macera Therapeutics and Innorna Co., Ltd Collaborate on CAR-M mRNA-LNP Technology

Fineline Cube May 11, 2024

Macera Therapeutics, a company based in Nanjing specializing in the development of macrophage immunotherapies, has...

Company Deals

Vazyme Biotech and SPH KDL Health Join Forces to Promote Alzheimer’s Blood Tests

Fineline Cube May 11, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), a prominent biotech company based in China, has entered...

Company Medical Device

Jiangsu BioPerfectus’ Dengue Detection Kit Gains NMPA Approval for Commercialization

Fineline Cube May 11, 2024

Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading in vitro diagnostic (IVD) product manufacturer...

Company Deals

DSciLab, mRNA Pharma Startup, Bags RMB 100 Million in Angel Financing Led by Fosun Health

Fineline Cube May 11, 2024

DSciLab Co., Ltd, a China-based mRNA pharmaceutical company nurtured by Fosun Health Capital, has announced...

Company Deals

Novo Nordisk Partners with Flagship Pioneering for Development of Novel Obesity Treatments

Fineline Cube May 11, 2024

Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced a partnership with life sciences venture...

Company

Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization

Fineline Cube May 11, 2024

US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter...

Company Deals

Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion

Fineline Cube May 11, 2024

France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ:...

Policy / Regulatory

China Unveils Sweeping 2024 Legislative Plan with Healthcare and Pharma at Forefront

Fineline Cube May 11, 2024

The State Council of China has released its annual legislative work plan for 2024, outlining...

Company Drug

MSD’s Keytruda Adjuvant Treatment for High-Risk Endometrial Cancer Fails to Meet Primary Endpoint

Fineline Cube May 10, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...

Company

Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip

Fineline Cube May 10, 2024

Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...

Company Drug

WestGene Biopharma’s Groundbreaking mRNA Vaccine for EB Virus Tumors Gets FDA Green Light

Fineline Cube May 10, 2024

WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug...

Company Drug

RJK Biopharma’s RJK002 Earns Tacit Approval for Amyotrophic Lateral Sclerosis Clinical Trial

Fineline Cube May 10, 2024

Shanghai-based RJK Biopharma Ltd. has announced that its Category 1 drug RJK002 has received tacit...

Company Deals Drug

BioNTech Secures Global Rights to Biotheus Inc.’s Pre-Clinical Bispecific Antibody

Fineline Cube May 10, 2024

Biotheus Inc., a biopharmaceutical company based in China, has announced that its German partner BioNTech...

Company Drug

China Grants Marketing Nod to Ferring Pharmaceuticals’ Rekovelle for Assisted Reproduction

Fineline Cube May 10, 2024

Switzerland-based Ferring Pharmaceuticals Ltd announced that its recombinant human follicle stimulating hormone δ injection, Rekovelle,...

Posts pagination

1 … 351 352 353 … 654

Recent updates

  • Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma
  • CSPC’s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status
  • AI Healthtech Firm WeiMai Files for Hong Kong IPO, Touting CareAI Platform and Leadership in Hospital-Linked Disease Management
  • UPC Appeal Court Reverses Lower Ruling, Imposes Preliminary Injunction on Sinocare’s iCanCGM App in 17 European Countries Following Abbott Patent Claim
  • Hengrui Launches Pediatric Trial of Dual GIPR/GLP-1R Agonist HRS9531 in Overweight and Obese Adolescents Following NMPA Clearance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

Company Drug

CSPC’s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status

Company Deals Digital

AI Healthtech Firm WeiMai Files for Hong Kong IPO, Touting CareAI Platform and Leadership in Hospital-Linked Disease Management

Company Legal / IP Medical Device

UPC Appeal Court Reverses Lower Ruling, Imposes Preliminary Injunction on Sinocare’s iCanCGM App in 17 European Countries Following Abbott Patent Claim

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.